Your session is about to expire
← Back to Search
Adaptive Radiotherapy + Chemotherapy for Head and Neck Cancer (DARTBOARD Trial)
DARTBOARD Trial Summary
This trial will study whether using DART with ML setup margins can increase the rate of tumor control and/or reduce toxicity compared to using DART with standard margins.
DARTBOARD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDARTBOARD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.DARTBOARD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had chemotherapy for this cancer before, but treatment for another cancer is okay.I agree to use effective birth control during and for 90 days after the study.My cancer is in the early stages and located in my vocal cords.I have cancer in areas other than the oropharynx, larynx, and hypopharynx, except for low-risk prostate or well-differentiated thyroid cancer.I had cancer before, but it's expected to stay away for less than 3 years.I do not have any severe illnesses that would stop me from following the study's requirements.I have a history of severe immune system problems, including HIV, or have had a transplant.I have been diagnosed with squamous cell carcinoma in my throat, but not from an unknown primary.My cancer is between stages I and IVB, but it's not in the early stages of glottic cancer.I have had radiation in the same area as my current cancer.I am a woman capable of becoming pregnant.I can take care of myself and am up and about more than half of the day.My cancer can be seen or measured on scans, or I've had a small biopsy.All of my cancer and affected lymph nodes have been surgically removed.I may have surgery through the mouth for early-stage cancer in my tonsil or base of tongue.My cancer has spread to distant parts of my body.You have had allergic reactions to similar medications or treatments that are similar to the chemotherapy drugs used in this study.I am 18 years old or older.I have not had my uterus or both ovaries removed.
- Group 1: Involved Nodal Radiotherapy with marginless Daily Adaptive Radiotherapy w or w/o chemotherapy
- Group 2: Involved Nodal Radiotherapy with conventional margins w or w/o chemotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are eligible to take part in this clinical research?
"Affirmative. Clinicaltrials.gov delineates that this clinical experiment, which was posted on February 23rd 2022, is currently recruiting participants. A total of 50 patients are needed to be recruited from one location."
Is this experiment actively seeking new participants?
"Clinicaltrials.gov highlights that this medical study is actively looking for participants, having been posted to the platform on February 23rd 2022 and last edited on August 19th of the same year."
Has the FDA granted approval to using Intensity modulated radiation therapy (IMRT) and/or chemotherapy?
"Our team at Power rated the safety of Intensity modulated radiation therapy with or without chemotherapy as a 2 on their scale, due to there being some evidence for safety but none for efficacy."
In what medical scenarios is Intensity modulated radiation therapy (IMRT) combined with chemotherapy commonly employed?
"IMRT, often combined with chemotherapy, can be a successful treatment for malignant neoplasms and metastatic colorectal cancer (CRC) in patients that are intolerant to irinotecan."
Share this study with friends
Copy Link
Messenger